RE:RE:RE:RE:EARNINGS before dec 30Yes, revenues declined Q3 to Q4. But that metric alone doesn't tell the story:
Year over year lossed reduced from 22m to 6m; comprehensive loss from 23m to 8m. Revenues no change, which is not positive, i.e., not showing growth but covid lockdowns have to be factored in here. Expenses down from 22m to 10m. Cash on hand up from 2.7 to 4.4m. Total equity up from 19 to 25m. Etc. Point being that all financial must be considered when making a judgment about company's financial health.
Company has been getting healthier ever since Rosen took over. Current sp is pricing for bankruptcy which is delusional given current finances, growth in NV market, company expansion of operations, and adjustment to product line.
Company statements: "
Progress has been made operationally across all entities and now management focus has shifted to improve revenue growth and overall financial performance. The Company believes its diversified product offerings and premium products will have a positive impact on revenues."
The proof is in the pot. Q1 report will show whether revenues are increasing. "The Company believes that it is on the right path to improve its growth and reach consistent profitability in Fiscal 2022."
Company doesn't offer a statement like that unless they know they will deliver. TGIF is a growth play. If/when they show improved revenue, and turn a profit, bleeding will stop, sp will rise. For now, market being ruled by short term investors, macro turmoil, not just in pot sector, and end of year selling, market is discounting likelihood of future growth. These things go in cycles. Lkg forward to Q1 report.